Navigation Links
PDI Announces Contract Extension With Revenue Value of Approximately $23 Million
Date:4/4/2011

PARSIPPANY, N.J., April 4, 2011 /PRNewswire/ -- PDI, Inc. (Nasdaq: PDII), a leading provider of integrated promotional outsource services to health care companies, today announced the extension of a contract sales engagement with an existing Top 5 global pharmaceutical client. The extension began April 1 and will run for the balance of 2011. This program is expected to generate total revenue to PDI of approximately $23 million.

Under the program, PDI will provide the client with a dedicated sales team that will call on primary care physicians.

"The extension of this engagement with a major client reaffirms the high return on investment and strategic flexibility that PDI is able to consistently provide to our customers," said Nancy Lurker, Chief Executive Officer of PDI, Inc. "As a company, we remain intensely focused on delivering optimal value to our customers by developing and deploying the most effective resources and technologies for communicating with physicians and other health care providers."

About PDI

PDI, with its interactive digital agency Group DCA, is a leading provider of integrated multichannel promotional outsource services to established and emerging health care companies. The company is dedicated to enhancing engagement with health care practitioners and optimizing commercial investments for its clients by providing strategic flexibility, innovative multichannel promotional solutions, and sales and marketing expertise. For more information, please visit the company's website at http://www.pdi-inc.com.

Forward-Looking Statements

This press release contains forward-looking statements regarding future events and financial performance. These statements are based on current expectations and assumptions involving judgments about, among other things, future economic, competitive
'/>"/>

SOURCE PDI, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... 2015   Synageva BioPharma Corp. (Synageva) ... developing therapeutic products for rare diseases, joins the ... Organisation for Rare Diseases™ (EURORDIS™), The Global Genes ... Rare Disease Day. On the last ... and other participants conduct special events to raise ...
(Date:2/27/2015)... Israel , February 27, 2015 /PRNewswire/ ... baut sein bahnbrechendes Überwachungssystem für kongestive Herzinsuffizienz ... aus -     ... Technologies, die ein neuartiges Herzüberwachungssystem für Patienten ... heute bekannt, dass sie ein Finanzierungsvorhaben über ...
(Date:2/26/2015)... SANTA CLARA, Calif. , Feb. 27, 2015  Finesse ... Finesse Solutions announced the expansion of ... The opening is planned for mid-March and access for ... access from the A-563, and located adjacent to the ... occupied by the Finesse automation engineering team and allow Finesse ...
Breaking Medicine Technology:Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 2Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 3Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 4Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 5Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 6Vectorious Medical Technologies schließt Finanzierungsvorhaben über 5 Mio. USD ab 2New Finesse Office in United Kingdom 2
... EMERYVILLE, Calif., Oct. 26, 2011 Bionovo, Inc. (Nasdaq: ... the discovery and development of safe and effective treatments ... has started to the Phase 3 pivotal clinical trial ... Menerba™ (MF101) among a cohort of postmenopausal women for ...
... Inc. (Nasdaq: NBIX ) announced today that the ... the Nasdaq market closes on Monday,  October 31, 2011.  Neurocrine ... discuss its financial results and provide a Company update Monday ... p.m. Pacific Time). Participants can access the live ...
Cached Medicine Technology:Bionovo Initiates Menerba (MF101) Phase 3 Clinical Trial for Menopausal Hot Flashes 2Bionovo Initiates Menerba (MF101) Phase 3 Clinical Trial for Menopausal Hot Flashes 3Bionovo Initiates Menerba (MF101) Phase 3 Clinical Trial for Menopausal Hot Flashes 4
(Date:3/1/2015)... 28, 2015 CrossFit Attollo is a CrossFit ... offering a special discount to new members. Now through ... a three month contract will receive their fourth month half ... cost members $440. The three month contract is only ... then the fourth month comes in at only $55. The ...
(Date:2/28/2015)... 28, 2015 Gerald “Solutionman” Haman surveyed ... or barriers to innovative thinking. “The #1 block ... lack of tools,” reports Haman, who created the Thinkubator ... of people felt that they did not have enough ... and resources to stimulate innovation. , Solutionman’s monthly “Accelerating ...
(Date:2/28/2015)... 2015 Mew and Company, a Vancouver ... now provide business consulting services in addition to a ... planning and succession planning. Company finances are a complicated ... On top of this, complex Canadian tax laws can ... As a result, Mew and Company works to advise ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 The ... its annual awards at the International Symposium on Malignant ... be held at the Hyatt Regency Bethesda in Bethesda, ... their dedicated work and commitment to the mission to ... Year Award will be presented to Miriam Ratner. Miriam ...
(Date:2/28/2015)... 28, 2015 A case management conference ... that have been filed by law firms including Bernstein ... in March, the Firm notes. , According to ... in the federal litigation will meet on March 13, ... prescription therapy treatments designed to raise levels of the ...
Breaking Medicine News(10 mins):Health News:CrossFit Gym in Vancouver WA Offers Spring Special 2Health News:New Survey Reveals “Lack of Time” Is the Number #1 Barrier to Innovative Thinking 2Health News:New Survey Reveals “Lack of Time” Is the Number #1 Barrier to Innovative Thinking 3Health News:Vancouver Corporate Tax Accountants Now Provide Business Consulting Services 2Health News:Cancer Research Foundation Honors Award Recipients 2Health News:Cancer Research Foundation Honors Award Recipients 3Health News:Cancer Research Foundation Honors Award Recipients 4Health News:Bernstein Liebhard LLP Notes Approaching Conference in Federal Litigation that Includes Numerous Testosterone Lawsuits Filed by the Firm 2Health News:Bernstein Liebhard LLP Notes Approaching Conference in Federal Litigation that Includes Numerous Testosterone Lawsuits Filed by the Firm 3Health News:Bernstein Liebhard LLP Notes Approaching Conference in Federal Litigation that Includes Numerous Testosterone Lawsuits Filed by the Firm 4
... Boniva, Zometa does not apply to obese women, however , ... drugs used to prevent and treat osteoporosis might reduce the ... study, which included 6,000 Wisconsin women aged 20 to 69, ... Boniva and Zometa for more than two years were 40 ...
... ... ... , ... , , , ...
... ... a new partnership with leading SolidWorks and Agile PLM reseller GoEngineer to distribute DesignState ... "best-in-class" tools to manage engineering data and collaborate across the enterprise with Oracle,s ... ...
... ... of a new resource that may help put some of your questions to bed. BestFoodFacts.org, ... the country to weigh in on what’s true, plausible, unknown, misguided or just plain false. ... (PRWEB) March 5, 2010 ...
... ... that society’s obligation and moral responsibility to remedy the tragic legacy of decades of ... follow? , ... March 5, 2010 -- The Mesothelioma Applied Research Foundation today publicly praised the United ...
... 39th Annual Meeting of the American Association for ... Convention Center in Washington, DC, lead researcher M. ... poster of a study titled "Epithelial-to-Endothelial Transition: An ... and a team of researchers have reported that ...
Cached Medicine News:Health News:Certain Bone Drugs May Lower Breast Cancer Risk 2Health News:Christiana Care Health System Wins National Award for Innovation 2Health News:Christiana Care Health System Wins National Award for Innovation 3Health News:Enterprise PDM Integration has Never Been Easier; Zero Wait-State Announces Leading SolidWorks Reseller GoEngineer as Master Distributor for DesignState 2Health News:Enterprise PDM Integration has Never Been Easier; Zero Wait-State Announces Leading SolidWorks Reseller GoEngineer as Master Distributor for DesignState 3Health News:BestFoodFacts.org -- Food, Fiber and Fuel Questions Answered 2Health News:U.K.: Justice for Asbestos Disease Victims Requires Mesothelioma Research Funding 2Health News:U.K.: Justice for Asbestos Disease Victims Requires Mesothelioma Research Funding 3
BD Beaver Cataract blade, 30.0 mm long x 2.2 mm wide, designed for ICCE and ECCE procedures, designed for ICCE and ECCE, sterile....
BD Beaver Chondroplastic blade, sharp on two sides, curved, sterile...
BD Beaver Meniscus blade, 7 mm flat (4/bx, 1 bx/ca), specially designed maximum leverage and visibility, cutting edge: 7 mm, sterile....
... accurate testing of large oculomotor ... Fits all standard trial frames. ... of thin optical quality acrylic ... includes a display box. Available ...
Medicine Products: